



WCLC 2022 Industry Sponsored Symposium

INVITATION

EXPANDING HORIZONS FOR THE TARGETED MANAGEMENT OF EGFR-MUTANT NSCLC

**Sunday
7 August 2022**

**Symposium
13:15-14:15 CEST**

Strauss 3
Messe Wien Exhibition &
Congress Center, Vienna

STEERING COMMITTEE

Martin Reck, Germany
Umberto Malapelle, Italy

FACULTY

Maximilian Hochmair, Austria
Sabine Merkelbach-Bruse, Germany
Jordi Remon, Spain

LEARNING OBJECTIVES

After attending this symposium, participants should be able to:

- Reflect on recent developments in the molecular diagnosis of EGFR-mutant NSCLC
- Describe updates in the management of advanced EGFR-mutant NSCLC
- Evaluate the use of novel emerging therapeutic options for EGFR exon 20 insertion mutations and their implementation into clinical practice

This program was approved by the IASLC 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

Unable to join us in Vienna?
Scan the QR code to join us
live via the OME platform



www.ome-forum.com

AGENDA

- Welcome and introductions
- What's new in molecular diagnostics for EGFR-mutant NSCLC?
- EGFR exon 20 insertion mutations: A new target for an old mutation
- Novel approaches in treatment-resistant advanced EGFR-mutant NSCLC
- Live Q&A
- Key learnings and closing remarks



This invitation is for healthcare professionals only
With the support of Janssen Pharmaceutical
Companies of Johnson & Johnson in EMEA
Janssen Pharmaceutica NV, Turnhoutseweg 30,
B-2340 Beerse, Belgium
Date of preparation: June 2022 EM-102376



PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*

Copyright © 2022 Janssen Pharmaceutica NV